Kairos Pharma Ltd. (KAPA)
| Bid | 0.81 |
| Market Cap | 14.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.6M |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -3.77 |
| Forward PE | -2.05 |
| Analyst | Buy |
| Ask | 0.95 |
| Volume | 37,409 |
| Avg. Volume (20D) | 392,138 |
| Open | 0.87 |
| Previous Close | 0.85 |
| Day's Range | 0.85 - 0.87 |
| 52-Week Range | 0.80 - 4.00 |
| Beta | 2.87 |
About KAPA
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, Califo...
Analyst Forecast
According to 4 analyst ratings, the average rating for KAPA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 938.06% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, C...
